Gemphire Therapeutics Inc. (NASDAQ:GEMP) has been assigned an average rating of “Buy” from the six ratings firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $25.00.

Several equities analysts recently commented on GEMP shares. Canaccord Genuity reissued a “buy” rating and set a $17.00 price target on shares of Gemphire Therapeutics in a research report on Wednesday, May 31st. Jefferies Group LLC set a $17.00 price target on Gemphire Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, May 31st. Zacks Investment Research raised Gemphire Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price target on the stock in a research report on Wednesday, July 19th. Finally, HC Wainwright started coverage on Gemphire Therapeutics in a research report on Thursday, August 31st. They set a “buy” rating and a $21.00 price target on the stock.

Institutional investors have recently added to or reduced their stakes in the stock. Advisory Services Network LLC purchased a new stake in Gemphire Therapeutics during the 2nd quarter worth approximately $139,000. GM Advisory Group Inc. purchased a new stake in Gemphire Therapeutics during the 2nd quarter worth approximately $457,000. Vanguard Group Inc. increased its holdings in Gemphire Therapeutics by 137.6% during the 2nd quarter. Vanguard Group Inc. now owns 30,898 shares of the company’s stock worth $399,000 after purchasing an additional 17,892 shares during the last quarter. Cambridge Investment Research Advisors Inc. increased its holdings in Gemphire Therapeutics by 1.7% during the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 153,064 shares of the company’s stock worth $1,959,000 after purchasing an additional 2,500 shares during the last quarter. Finally, Northpointe Capital LLC purchased a new stake in Gemphire Therapeutics during the 2nd quarter worth approximately $3,472,000. 29.73% of the stock is currently owned by hedge funds and other institutional investors.

Gemphire Therapeutics (NASDAQ:GEMP) traded up 0.80% during mid-day trading on Friday, hitting $10.11. 92,538 shares of the company were exchanged. The firm has a 50 day moving average price of $12.16 and a 200 day moving average price of $11.42. Gemphire Therapeutics has a 12 month low of $7.20 and a 12 month high of $21.59. The stock’s market cap is $107.43 million.

Gemphire Therapeutics (NASDAQ:GEMP) last released its quarterly earnings results on Monday, August 14th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.71) by $0.28. Analysts anticipate that Gemphire Therapeutics will post ($3.18) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/09/09/gemphire-therapeutics-inc-gemp-given-consensus-recommendation-of-buy-by-brokerages.html.

About Gemphire Therapeutics

Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.

Analyst Recommendations for Gemphire Therapeutics (NASDAQ:GEMP)

Receive News & Ratings for Gemphire Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.